Molecular Neurobiology,
Journal Year:
2023,
Volume and Issue:
60(12), P. 7104 - 7117
Published: Aug. 2, 2023
Abstract
Amyotrophic
lateral
sclerosis
(ALS)
is
a
progressive
motor
neuron
disease
that
affects
nerve
cells
in
the
brain
and
spinal
cord,
causing
loss
of
muscle
control,
atrophy
later
stages,
death.
Diagnosis
has
an
average
delay
1
year
after
symptoms
onset,
which
impairs
early
management.
The
identification
specific
biomarker
could
help
decrease
diagnostic
delay.
MicroRNA
(miRNA)
expression
levels
have
been
proposed
as
ALS
biomarkers,
altered
function
reported
pathogenesis.
aim
this
study
was
to
assess
differential
plasma
miRNAs
patients
two
control
populations
(healthy
controls
ALS-mimic
disorders).
For
that,
16
samples
from
each
group
were
pooled,
then
1008
assessed
through
reverse
transcription-quantitative
polymerase
chain
reaction
(RT-qPCR).
From
these,
ten
candidate
selected
validated
35
patients,
disorders
15
healthy
controls.
We
also
same
different
time
points
progression.
Although
we
unable
determine
miRNA
signature
use
or
condition
marker,
found
miR-7-2-3p,
miR-26a-1-3p,
miR-224-5p
miR-206
are
good
candidates
understand
pathophysiology
ALS.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(11), P. 5573 - 5573
Published: May 21, 2024
Abiraterone
acetate
(AA)
serves
as
a
medication
for
managing
persistent
testosterone
production
in
patients
with
metastatic
castration-resistant
prostate
cancer
(mCRPC).
However,
its
efficacy
varies
among
individuals;
thus,
the
identification
of
biomarkers
to
predict
and
follow
treatment
response
is
required.
In
this
pilot
study,
we
explored
potential
circulating
microRNAs
(c-miRNAs)
stratify
based
on
their
responsiveness
AA.
We
conducted
an
analysis
plasma
samples
obtained
from
cohort
33
mCRPC
before
after
three,
six,
nine
months
AA
treatment.
Using
miRNA
RT-qPCR
panels
candidate
discovery
TaqMan
validation,
identified
promising
signatures.
Our
investigation
indicated
that
signature
miR-103a-3p
miR-378a-5p
effectively
discriminates
between
non-responder
responder
patients,
while
also
following
drug's
over
time.
Additionally,
through
silico
analysis,
target
genes
transcription
factors
two
miRNAs,
including
PTEN
HOXB13,
which
are
known
play
roles
resistance
mCRPC.
summary,
our
study
highlights
c-miRNAs
companion
diagnostics
offering
novel
insights
informed
decision-making
Current Neuropharmacology,
Journal Year:
2024,
Volume and Issue:
23(2), P. 209 - 231
Published: Aug. 12, 2024
The
identification
of
specific
circulating
miRNAs
has
been
proposed
as
a
valuable
tool
for
elucidating
the
pathophysiology
brain
damage
or
injury
and
predicting
patient
outcomes.
Frontiers in Neuroscience,
Journal Year:
2024,
Volume and Issue:
18
Published: Nov. 8, 2024
Neurodegenerative
diseases
(NDs)
are
increasingly
prevalent
in
our
aging
population,
imposing
significant
social
and
economic
burdens.
Currently,
most
ND
patients
receive
only
symptomatic
treatment
due
to
limited
understanding
of
their
underlying
causes.
Consequently,
there
is
a
pressing
need
for
comprehensive
research
into
the
pathological
mechanisms
NDs
by
both
researchers
clinicians.
Autophagy,
cellular
mechanism
responsible
maintaining
equilibrium
removing
dysfunctional
organelles
misfolded
proteins,
plays
vital
role
cell
health
implicated
various
diseases.
MicroRNAs
(miRNAs)
exert
influence
on
autophagy
hold
promise
treating
these
These
small
oligonucleotides
bind
3'-untranslated
region
(UTR)
target
mRNAs,
leading
mRNA
silencing,
degradation,
or
translation
blockade.
This
review
explores
recent
findings
regulation
autophagy-related
genes
different
miRNAs
conditions,
including
neurodegeneration
inflammation-related
The
recognition
as
key
regulators
human
has
spurred
investigations
pharmacological
compounds
traditional
medicines
targeting
disease
models.
catalyzed
new
wave
therapeutic
interventions
aimed
at
modulating
autophagy.
Molecular Neurobiology,
Journal Year:
2023,
Volume and Issue:
60(12), P. 7104 - 7117
Published: Aug. 2, 2023
Abstract
Amyotrophic
lateral
sclerosis
(ALS)
is
a
progressive
motor
neuron
disease
that
affects
nerve
cells
in
the
brain
and
spinal
cord,
causing
loss
of
muscle
control,
atrophy
later
stages,
death.
Diagnosis
has
an
average
delay
1
year
after
symptoms
onset,
which
impairs
early
management.
The
identification
specific
biomarker
could
help
decrease
diagnostic
delay.
MicroRNA
(miRNA)
expression
levels
have
been
proposed
as
ALS
biomarkers,
altered
function
reported
pathogenesis.
aim
this
study
was
to
assess
differential
plasma
miRNAs
patients
two
control
populations
(healthy
controls
ALS-mimic
disorders).
For
that,
16
samples
from
each
group
were
pooled,
then
1008
assessed
through
reverse
transcription-quantitative
polymerase
chain
reaction
(RT-qPCR).
From
these,
ten
candidate
selected
validated
35
patients,
disorders
15
healthy
controls.
We
also
same
different
time
points
progression.
Although
we
unable
determine
miRNA
signature
use
or
condition
marker,
found
miR-7-2-3p,
miR-26a-1-3p,
miR-224-5p
miR-206
are
good
candidates
understand
pathophysiology
ALS.
